Nosiheptide biosynthesis featuring a unique indole side ring formation on the characteristic thiopeptide framework.
Nosiheptide (NOS), belonging to the e series of thiopeptide antibiotics that exhibit potent activity against various bacterial pathogens, bears a unique indole side ring system and regiospecific hydroxyl groups on the characteristic macrocyclic core. Here, cloning, sequencing, and characterization of the nos gene cluster from Streptomyces actuosus ATCC 25421 as a model for this series of thiopeptides has unveiled new insights into their biosynthesis. Bioinformatics-based sequence analysis and in vivo investigation into the gene functions show that NOS biosynthesis shares a common strategy with recently characterized b or c series thiopeptides for forming the characteristic macrocyclic core, which features a ribosomally synthesized precursor peptide with conserved posttranslational modifications. However, it apparently proceeds via a different route for tailoring the thiopeptide framework, allowing the final product to exhibit the distinct structural characteristics of e series thiopeptides, such as the indole side ring system. Chemical complementation supports the notion that the S-adenosylmethionine-dependent protein NosL may play a central role in converting tryptophan to the key 3-methylindole moiety by an unusual carbon side chain rearrangement, most likely via a radical-initiated mechanism. Characterization of the indole side ring-opened analogue of NOS from the nosN mutant strain is consistent with the proposed methyltransferase activity of its encoded protein, shedding light into the timing of the individual steps for indole side ring biosynthesis. These results also suggest the feasibility of engineering novel thiopeptides for drug discovery by manipulating the NOS biosynthetic machinery.
Yu
Yi
Y
State Key Laboratory of Bioorganic and Natural Products Chemistry, Shanghai Institute of Organic Chemistry, Chinese Academy of Sciences, Shanghai 200032, China.
Duan
Lian
L
Zhang
Qi
Q
Liao
Rijing
R
Ding
Ying
Y
Pan
Haixue
H
Wendt-Pienkowski
Evelyn
E
Tang
Gongli
G
Shen
Ben
B
Liu
Wen
W
D000595:Amino Acid Sequence; D000900:Anti-Bacterial Agents / Q000737:chemistry / Q000378:metabolism*; D015964:Gene Expression Regulation, Bacterial; D005798:Genes, Bacterial; D008969:Molecular Sequence Data; D015394:Molecular Structure; D005810:Multigene Family; D010452:Peptide Biosynthesis; D013302:Streptomyces / Q000235:genetics*; D013844:Thiazoles / Q000737:chemistry / Q000378:metabolism
D000900:Anti-Bacterial Agents; D013844:Thiazoles; C014134:nosiheptide
Annu Rev Microbiol. 2007;61:477-501
17506681
Chem Rev. 2006 Aug;106(8):3468-96
16895337
Chem Biol. 2009 Feb 27;16(2):141-7
19246004
Bioorg Med Chem Lett. 2005 Apr 15;15(8):2069-72
15808470
Antimicrob Agents Chemother. 2004 Oct;48(10):3697-701
15388422
Bioorg Med Chem Lett. 2008 Jul 15;18(14):4051-3
18556203
Mol Biosyst. 2007 Jan;3(1):60-74
17216057
J Am Chem Soc. 1977 Sep 14;99(19):6418-23
893891
Chem Rev. 2005 Feb;105(2):715-38
15700962
J Am Chem Soc. 2009 Apr 29;131(16):5946-55
19338336
Proc Natl Acad Sci U S A. 2008 Apr 15;105(15):5879-84
18375757
Bioorg Med Chem. 1996 Jul;4(7):1135-47
8831986
Bioorg Med Chem Lett. 2004 Nov 15;14(22):5573-7
15482927
Proc Natl Acad Sci U S A. 2009 Feb 24;106(8):2549-53
19196969
J Am Chem Soc. 2009 Apr 1;131(12):4327-34
19265401
J Antibiot (Tokyo). 1989 Nov;42(11):1643-8
2584148
Nat Chem Biol. 2008 Jun;4(6):341-3
18425112
Nature. 1977 Jan 13;265(5590):189-90
834263
Chem Rev. 2005 Feb;105(2):685-714
15700961
Poult Sci. 1980 Jul;59(7):1405-15
6994088
Angew Chem Int Ed Engl. 2007;46(48):9223-6
17969213
Experientia. 1980 Apr 15;36(4):414-6
7379912
Proc Natl Acad Sci U S A. 2008 Apr 15;105(15):5655-6
18398003
J Antibiot (Tokyo). 2003 Mar;56(3):232-42
12760679
Bioorg Med Chem Lett. 2006 Jul 1;16(13):3545-9
16621551
J Biol Chem. 2004 Sep 24;279(39):40505-10
15271986
J Antibiot (Tokyo). 2003 Mar;56(3):226-31
12760678